Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24463268 | 0.76 | KDM4E (0.51) | ALOX15HTTCYP11B1CYP11B2 | |
| SCHEMBL30390978 | 0.76 | KDM4E (0.51) | ALOX15HTTCYP11B1CYP11B2 | |
| SCHEMBL24463595 | 0.75 | PDE10A (0.41) | MCHR1PDE10ATLR7 | |
| SCHEMBL24463608 | 0.75 | BRD4 (0.37) | MCHR1PDE10ATLR7 | |
| SCHEMBL11874428 | 0.74 | PDE10A (0.41) | MCHR1PDE10A | |
| SCHEMBL24463611 | 0.72 | BRD4 (0.36) | MCHR1PDE10A | |
| SCHEMBL24463338 | 0.70 | CCNT1 (0.52) | CYP11B1CYP11B2 | |
| SCHEMBL24463627 | 0.70 | TLR7 (0.39) | MCHR1PDE10ATLR7 | |
| SCHEMBL3577361 | 0.69 | MCHR1 (0.44) | MCHR1PDE10A | |
| SCHEMBL3574868 | 0.69 | KDM4E (0.47) | HTTPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116057045-A | Fibroblast growth factor receptor kinase inhibitors | 金耐特生物制药公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-4161656-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | Kinnate Biopharma Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11345681-B1 | Inhibitors of fibroblast growth factor receptor kinases | KINNATE BIOPHARMA INC. (US) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345681-B1 | Inhibitors of fibroblast growth factor receptor kinases | FGFR1, FGFR2, FGFR3 | ALOX15 2895/4885HTT 2931/4885MCHR1 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.